Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials

(2020) Angelo Antonini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

(2020) Dieter Volc et al.   LANCET NEUROLOGY

A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy

(2020) Wassilios G. Meissner et al.   MOVEMENT DISORDERS

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

(2019) Miroslaw Brys et al.   MOVEMENT DISORDERS

α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities

(2019) Parvez Alam et al.   JOURNAL OF NEUROCHEMISTRY

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

(2019) Naomi P. Visanji et al.   Translational Neurodegeneration

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes

(2019) Yaping Chu et al.   BRAIN

Immunotherapy in Parkinson’s disease: Current status and future directions

(2019) Diptaman Chatterjee et al.   NEUROBIOLOGY OF DISEASE

Vaccine-associated hypersensitivity

(2018) Michael M. McNeil et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

(2018) Joseph Jankovic et al.   JAMA Neurology

Therapeutic approaches to target alpha-synuclein pathology

(2017) Patrik Brundin et al.   EXPERIMENTAL NEUROLOGY

Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies

(2017) Tomasz Brudek et al.   Molecular Neurodegeneration

Can immunotherapy treat neurodegeneration?

(2017) Michal Schwartz   SCIENCE

Parkinson disease

(2017) Werner Poewe et al.   Nature Reviews Disease Primers

Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism

(2015) Stanley B. Prusiner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

(2014) Markus Mandler et al.   ACTA NEUROPATHOLOGICA

Axonopathy in an α-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal–Truncated α-Synuclein

(2013) Dora Games et al.   AMERICAN JOURNAL OF PATHOLOGY

Thinking laterally about neurodegenerative proteinopathies

(2013) Todd E. Golde et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

(2013) Elvira Valera et al.   PHARMACOLOGY & THERAPEUTICS

AFFITOME® technology in neurodegenerative diseases: The doubling advantage

(2011) Achim Schneeberger et al.   Human vaccines & immunotherapeutics

Controlling the mass action of α-synuclein in Parkinson’s disease

(2008) Changyoun Kim et al.   JOURNAL OF NEUROCHEMISTRY

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS